skip to main content

Claudin-18.2 Zolbetuximab — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGI CancersClaudin-18.2 ZolbetuximabSCE Medical Oncology

A 58-year-old woman with advanced gastric cancer is tested for Claudin-18.2 expression. Her tumour is Claudin-18.2 positive (IHC ≥75% of cells with ≥2+ staining). What is the emerging targeted therapy?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Zolbetuximab (anti-Claudin-18.2 monoclonal antibody) + chemotherapy showed significant PFS and OS benefit in Claudin-18.2-positive gastric cancer (SPOTLIGHT and GLOW trials)

Claudin-18.2 is a tight junction protein expressed in ~38% of gastric cancers. Zolbetuximab (anti-CLDN18.2 mAb) + FOLFOX (SPOTLIGHT) or CAPOX (GLOW) showed PFS and OS benefit in CLDN18.2-positive, HER2-negative gastric cancer. This represents a new biomarker-driven treatment axis alongside HER2 and PD-L1 in gastric cancer. NICE appraisal pending.

Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer